Research on VOLITIONRX (VNRX:NYSE) , CANTARGIA (CANTA:STO) , Irlab Therapeutics Ab (IRLABA:STO) , AAC Clyde Space Ab (AAC:STO) , SenSen Networks Ltd. (SNS:ASX) , Vection Technologies Ltd. (VR1:ASX) , Bankers Investment Trust PLC GBP (BNKR:LON) , UIL Limited (UTL:LON) , Cliq Digital AG (CLIQ:ETR) , Esker (ALESK:EPA) , Claranova SE (ALCLA:PAR) , Centaur Media plc (CAU:LON) , Checkit plc (CKT:LON) , Quadrise PLC (QED:LON) , BlackRock American Income Trust plc GBP (BRAI:LON) , Metro Bank Holdings Plc (MTRO:LON) , AUSTRIACARD HOLDINGS AG (ACAG:ATH) , Arctic Paper S.A. (ATC:WAR) , Tinexta SpA (TNXT:MIL) , ArborGen Holdings Limited (ARB:NZE) , Verve Group SE Class A (VER:OME) , AAC Clyde Space AB (AAC:OME) , Cantargia AB (CANTA:OME) , Nano Dimension Ltd Sponsored ADR (NNDM:NAS) , Substrate Artificial Intelligence SA (SAI:MCE) , Altus Midstream Co (ALTM:NYSE) , VolitionRX Ltd (VNRX:ASE) , Dar Global Plc (DAR:LON) from Edison
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.